On May 13, 2025, RBC Capital, led by analyst Brian Abrahams, issued an update on Karyopharm Therapeutics (KPTI, Financial), adjusting its price target. The firm maintained its "Outperform" rating on Karyopharm Therapeutics, indicating continued confidence in the stock's performance. However, RBC Capital lowered the price target from $34.00 USD to $33.00 USD, marking a 2.94% decrease in the target price.
The adjustment reflects RBC Capital's latest assessment of Karyopharm Therapeutics' market trajectory, with a focus on aligning expectations with current market conditions. Despite the lowered price target, the consistent "Outperform" rating suggests that RBC Capital sees strong potential in KPTI's future growth.
This update is significant for investors tracking Karyopharm Therapeutics (KPTI, Financial) on the NASDAQ, as it highlights both a cautious adjustment in potential valuation and confidence from RBC Capital in the stock's upcoming performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Karyopharm Therapeutics Inc (KPTI, Financial) is $37.25 with a high estimate of $67.50 and a low estimate of $10.00. The average target implies an upside of 620.50% from the current price of $5.17. More detailed estimate data can be found on the Karyopharm Therapeutics Inc (KPTI) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Karyopharm Therapeutics Inc's (KPTI, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Karyopharm Therapeutics Inc (KPTI, Financial) in one year is $18.73, suggesting a upside of 262.28% from the current price of $5.17. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Karyopharm Therapeutics Inc (KPTI) Summary page.
